India Speed-Up For Phase I Trial Approvals Draws Criticism
This article was originally published in PharmAsia News
India's effort to step up its approval process for Phase I trials has drawn warnings from critics that the lack of expertise could be a problem. Currently, India allows only drug makers who have developed their drugs in the country to conduct early-stage trials. The government is trying to reduce its approval time for those trials, drawing criticism from some experts. The Indian drug industry is pressuring the government to reduce its approval time to 30 days, similar to the practice in Western countries. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.